<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">16288661</PMID>
        <DateCompleted>
            <Year>2007</Year>
            <Month>07</Month>
            <Day>24</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2020</Year>
            <Month>09</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1472-6890</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>5</Volume>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Nov</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC clinical pathology</Title>
                <ISOAbbreviation>BMC Clin Pathol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Touchdown General Primer (GP5+/GP6+) PCR and optimized sample DNA concentration support the sensitive detection of human papillomavirus.</ArticleTitle>
            <Pagination>
                <MedlinePgn>10</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The GP5+/GP6+ PCR assay is a well-established HPV detection technique. This study has examined the effects of incorporating 'hot start' and 'touchdown' steps into the protocol. In addition, dTTP was substituted with dUTP to permit contamination control measures against carry-over PCR product.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Firstly, HPV-16 was amplified from SiHa cell DNA (0.1 ng-100 ng) diluted in a background of C-33A DNA (100 ng-2 microg). Secondly, the detection of small quantities (15ag-1.5pg) of HPV recombinant plasmids (types 16, 31, 33, 45, 51, 52, and 56) diluted in C-33A DNA was investigated. Thirdly, clinical sample DNA extracts (cervical smears, formalin-fixed vaginal lesions and breast tumors) were tested for HPV. Six different PCR protocols were assessed. HPV was detected by gel electrophoresis, and by Southern and dot blot hybridization.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">HPV detection sensitivity was dependent on the total amount of DNA in a PCR. Touchdown protocols supported HPV-16 detection from 1 ng or 0.5 ng SiHa cell DNA in a background of 2 microg or 1 microg C-33A DNA respectively, and from 0.1 ng of SiHa cell DNA (approximately 28 copies HPV-16) in 500 ng or 100 ng background DNA. Under standard GP5+/GP6+ annealing conditions, HPV-16 went undetected when the DNA content of a PCR was 2 microg or 1 microg, and with 500 ng C-33A DNA the sensitivity limit was 1 ng SiHa cell DNA. HPV recombinant plasmids were each detected with high (albeit varying) sensitivity by a touchdown protocol. HPV-31 was better amplified under standard annealing conditions (1.5fg in 100 ng background DNA) than by a touchdown approach (15fg detection limit). HPV-52 was not amplified by the standard protocol at the dilutions tested. Seventeen different HPV types were demonstrated in 47/65 (72%) abnormal cytology samples recorded as HPV negative by standard GP5+/GP6+ conditions. Twenty-one different HPV types were recorded in 111/114 (97%) vaginal lesions. Multiple infections were also detectable using a touchdown approach. Of 26 breast tumors, 5 (19%) tested HPV positive by the standard assay and 15/26 (58%) using a touchdown protocol.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Touchdown modification of the GP5+/GP6+ PCR assay enables the detection of HPV undetected under regular assay conditions. The use of standardized DNA quantities in a PCR rather than standard sample volumes containing arbitrary amounts of DNA is supported. A touchdown approach may be beneficial as an analytical test for the re-evaluation of (apparently) HPV negative abnormal cervical cytological or histological samples, and for investigating the association of HPV with disease conditions at diverse organ sites. The clinical utility of a touchdown approach for HPV detection requires further investigation as increased assay analytical sensitivity may not necessarily equate with improved clinical sensitivity or specificity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Evans</LastName>
                    <ForeName>Mark F</ForeName>
                    <Initials>MF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, University of Vermont, Burlington, Vermont 05405, USA. mark.evans@uvm.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adamson</LastName>
                    <ForeName>Christine S C</ForeName>
                    <Initials>CS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Simmons-Arnold</LastName>
                    <ForeName>Linda</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cooper</LastName>
                    <ForeName>Kumarasen</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2005</Year>
                <Month>11</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMC Clin Pathol</MedlineTA>
            <NlmUniqueID>101088665</NlmUniqueID>
            <ISSNLinking>1472-6890</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2005</Year>
                <Month>06</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2005</Year>
                <Month>11</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>11</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16288661</ArticleId>
            <ArticleId IdType="pii">1472-6890-5-10</ArticleId>
            <ArticleId IdType="doi">10.1186/1472-6890-5-10</ArticleId>
            <ArticleId IdType="pmc">PMC1314887</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Mod Pathol. 2002 Dec;15(12):1339-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12481016</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Hum Virol. 2001 Nov-Dec;4(6):329-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12082399</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 1992 Jun;65(6):891-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1319728</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pathol Res Pract. 1992 Apr;188(3):384-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1320761</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 1992;21(2):95-100</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1320958</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res. 2005;7(1):R1-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15642157</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nucleic Acids Res. 1992 Apr 11;20(7):1717-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1579465</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2005 Oct 17;93(8):946-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16222323</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nucleic Acids Res. 1991 Jul 25;19(14):4008</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1861999</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 1990 Jan;71 ( Pt 1):173-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2154534</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gene. 1990 Sep 1;93(1):125-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">2227421</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 1995 Aug;72(2):412-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7543772</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pathol. 1994 Sep;174(1):1-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7965398</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 1996;39(2):197-202</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8872328</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 1996;41(1):51-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8932876</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9049358</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 1997 Jul 29;72(3):412-5</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9247283</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer Res Treat. 1999 Jan;53(2):121-35</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10326789</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Microbiol. 1999 Aug;37(8):2508-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10405393</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Gen Virol. 1999 Jul;80 ( Pt 7):1725-33</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10423141</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 1999 Aug 18;91(16):1376-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10451442</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pathol. 1999 Sep;189(1):12-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10451482</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Microbiol. 2000 Jan;38(1):357-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10618116</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 2000 Jul 15;87(2):221-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10861478</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Breast Cancer. 2000 Jan;7(1):33-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11029768</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2001 Feb 21;93(4):293-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11181776</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 2001 Jan 17;93(2):148-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11208885</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Microbiol. 2002 Mar;40(3):779-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11880393</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Am J Obstet Gynecol. 2003 Jul;189(1):118-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12861148</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
